MedX Health Reports Financial Results for First Quarter - March 31, 2012
27 Mayo 2012 - 6:57PM
PR Newswire (Canada)
MISSISSAUGA, ON, May 30, 2012 /CNW/ - MedX Health Corp., (TSXV.MDX)
a global leader in drug free, non-invasive low level laser light
therapy for tissue repair and pain relief today reported their
revenues of $203,172 for the first quarter ended March 31, 2012,
representing a 60% increase from revenues of $126,960 for the
quarter ended March 31, 2011. The loss for the first quarter of
2012 was $357,791 or $0.01 per share compared to a loss of $213,513
or $0.01 per share for the first quarter of 2011. About MedX Health
Corp. MedX is a twelve (12) year old Canadian company,
headquartered in Mississauga, Ontario (Toronto), and is a global
leader in the design, manufacturing and distribution of quality low
level laser and light therapy technologies for use in numerous
medical settings, including rehab/chiropractic, dental, wound care,
and veterinary medicine, providing patients with drug free and
non-invasive treatment of tissue damage and pain. MedX laser and
light products are FDA approved, Health Canada cleared, and CE Mark
approved for use in North America as well as the European
Union. MedX Health acquired the worldwide assets of MoleMate
in June, 2011. For a complete profile of MedX Health Corp.
and its products visit www.medxhealth.com. About MoleMate Imaging
and Skin Cancer MoleMate recently received approval from Health
Canada, and is immediately available and in stock for all Canadian
physicians, joining their colleagues in Europe, the UK, Australia,
and the US, who have been utilizing this new pain-free,
non-invasive imaging system to 'See More', approximately 2mm below
the surface of suspicious moles, and provide additional information
and images related to every mole and all types of melanomas and
non-melanomas. MoleMate uses a patented device and technology that
features a hand-held scanner designed for office use that utilizes
light to view beneath suspicious moles or lesions in a pain free,
non-invasive manner, creating images for physicians to evaluate all
types of moles and lesions within seconds, providing images that
can reveal if a mole is benign, or something more serious, often
eliminating the need for skin biopsies, resulting in less pain,
scarring, and expense. Physicians interested in learning more
should contact MedX Health Corp. at www.simsys-molemate.com. This
press release does not constitute an offer of any securities for
sale. This press release contains certain forward-looking
statements within the meaning of applicable Canadian securities
legislation. These forward-looking statements involve certain
risks and uncertainties that could cause actual results to differ,
including, without limitation, the company's limited operating
history and history of losses, the inability to successfully obtain
further funding, the inability to raise capital on terms acceptable
to the company, the inability to compete effectively in the
marketplace, the inability to complete the proposed acquisition and
such other risks that could cause the actual results to differ
materially from those contained in the company's projections or
forward-looking statements. All forward-looking statements in
this press release are based on information available to the
company as of the date hereof, and the company undertakes no
obligation to update forward-looking statements to reflect events
or circumstances occurring after the date of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this press
release. MedX Health Corp. CONTACT: Investors:Steve Guillen /
President and Chief Executive OfficerMedX Health Corp.
investor@medxhealth.comPhone: (905) 670-4428
Copyright
Medx Health (TSXV:MDX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Medx Health (TSXV:MDX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024